Industry News

DSM Biomedical and CID Partnership Continues to Advance Device Deliverability With the Use of DSM ComfortCoat® Hydrophilic Coating

Published on 2010-04-22. Author : SpecialChem

GELEEN, NL -- DSM Biomedical, a global leader in biomedical materials science, announced the extension of its partnership with CID based on the use of DSM ComfortCoat® Hydrophilic coating technology on the Optima Jet Stent Delivery System and the Fluydo PTCA Balloon Catheter, both with CE mark and launched on the European market last month.

The DSM ComfortCoat® Hydrophilic Coating was designed to enhance maneuverability of devices in minimally invasive procedures. This advanced lubricious hydrophilic coating on the distal part of the Optima Jet shaft facilitates the treatment of more complex anatomies. Additionally, the DSM ComfortCoat® Hydrophilic Coating on the Fluydo PTCA Balloon contributes to further advance device deliverability in order to reach and cross the most difficult lesions.

"Following the successful launch of our bio-inducer surfaced stent Avantgarde last year and our continuous commitment to create new devices, we are excited to extend our partnership with DSM Biomedical in improving the quality of medical treatments. We value DSM Biomedical's long-standing experience in biomaterials, and their commitment to support with innovative new materials that lead to positive medical outcomes", said Mr. Franco Vallana, Chief Executive Officer, CID.

"Our partnership with CID is based on our shared vision of being dedicated to improving the quality of patient care and after-care through enabling innovation in medical solutions. We look forward to collaborating with them on future technologies", said John Marugg, DSM Biomedical's Business Director for ComfortCoat® medical coatings.

About DSM Biomedical:

DSM Biomedical develops novel materials-based solutions to meet the present and future needs of the medical device and biopharmaceutical industries. Building on the expertise and strengths of DSM and its acquisition of The Polymer Technology Group, which is now known as DSM PTG, the company's product portfolio includes coatings, drug delivery platforms and a wide range of biomedical materials for use in short- and long-term implantable medical devices. Key product brands include Bionate® PCU and CarboSil® TSPCU, two of the most extensively tested biomedical polymers ever developed. Both polymers have excellent biostability, high strength and abrasion resistance, making them candidate materials for load-bearing orthopedic implants. ComfortCoat® hydrophilic and antimicrobial coating technology for catheters, guidewires and stent delivery systems; and Dyneema Purity®, a high-performance polyethylene fiber technology developed specifically for use in medical applications, such as orthopedic implants. The company also markets the Trancerta™ family of bioresorbable materials for drug delivery. This portfolio is based on DSM's core strengths in materials science combined with its extensive in-house library of synthesis methods, formulation and processing techniques.

About DSM:

Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic prosperity, environmental quality and social equity, which it pursues simultaneously and in parallel. DSM has annual net sales of about €8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam.

About CID:

CID (Carbostent & Implantable Devices) is dedicated to contributing to human welfare by improving the quality of patient care and after-care through the development of innovative, minimally invasive implantable devices, procedures and therapies. A strong background in the field of implantable cardiovascular devices and haemocompatible materials, expressed in a remarkable IP portfolio, and a management with an expertise gained in many years of research, development and clinical experience, allow CID to offer the investors a fair return and its customers the necessary tools to meet new challenges.

Source: DSM

Omya Calcium Carboantes
Back to Top